Document Detail


Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study.
MedLine Citation:
PMID:  23756850     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Chronic hepatitis B virus (HBV) carrier status has a critical impact on clinical management of patients with IgA nephropathy (IgAN) who are treated with corticosteroids, because corticosteroids may enhance HBV replication. This study compared corticosteroids and antivirals combined therapy with corticosteroids monotherapy on patients of IgAN who were also HBV carriers. METHODS: This was a prospective, open-label cohort study on Chinese adults of HBV inactive carriers with concurrent IgAN (proteinuria ≥3.5 g/day). The patients were self-assigned to combined therapy group (prednisolone + lamivudine) or monotherapy group (prednisolone). Prednisolone 1 mg/kg/day for 2 months, tapered gradually, duration 12 months. Lamivudine (100 mg/day) was administrated 2 weeks before starting prednisolone and maintained 6 months after prednisolone withdrawal. All patients were followed up for 18 months. Outcome measures were rates of complete remission of proteinuria (<0.5 g/day), persistent massive proteinuria (≥3.5 g/day), HBV reactivation (detectable serum HBV-DNA or HBeAg), and significant alanine aminotransferase (ALT) elevation (>120 μ/L). RESULTS: Except 3 patients were lost to follow-up, 46 patients (29 of combined therapy group, 17 of monotherapy group) were included in the analysis. There were no differences in baseline characteristics of clinical and histopathological features between two groups (p > 0.05). At the end of follow-up, 19/29 (65.52 %) in combined therapy group and 9/17 (52.94 %) in monotherapy group achieved complete remission of proteinuria (p = 0.399), while 0/29 (0 %) and 2/17 (11.76 %) remained persistent massive proteinuria (p = 0.059). HBV reactivation and significant ALT elevation was 3/17 (17.65 %) of patients in monotherapy group, more than 0/29 (0 %) of combined therapy group (p = 0.019). Three HBV recurrent patients using prednisolone monotherapy were all male and young, with relatively short term of HBV infection history, HBV reactivation and severe liver impairment developed after 3 months of corticosteroids treatment, and daily proteinuria increased remarkably after prednisolone withdrawal. CONCLUSIONS: This study successfully treated with combined lamivudine and prednisolone in inactive HBV carriers with IgAN. We believe the combination of prednisolone and lamivudine was more efficacious than prednisolone alone in providing long-term viral suppression and liver enzyme normalization in inactive HBV carrier with IgAN.
Authors:
Jing Fang; Wenge Li; Zhao Tan; Duo Li
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-6-12
Journal Detail:
Title:  International urology and nephrology     Volume:  -     ISSN:  1573-2584     ISO Abbreviation:  Int Urol Nephrol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-6-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0262521     Medline TA:  Int Urol Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Nephrology, China-Japan Friendship Hospital, No. 2 East Yinghua Street, Chaoyang District, Beijing, 100029, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modelling a Wolbachia Invasion Using a Slow-Fast Dispersal Reaction-Diffusion Approach.
Next Document:  Successful LCL reconstruction and PCL repair for LCL tear and PCL avulsion following total knee arth...